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Abstract
Objective: To identify cross-border international registries for rare endocrine conditions that are led from Europe and 
to understand the extent of engagement with these registries within a network of reference centres (RCs) for rare 
endocrine conditions.
Methods: Database search of international registries and a survey of RCs in the European Reference Network for rare 
endocrine conditions (Endo-ERN) with an overall response rate of 82%.
Results: Of the 42 conditions with orphacodes currently covered within Endo-ERN, international registries exist for  
32 (76%). Of 27 registries identified in the Orphanet and RD-Connect databases, Endo-ERN RCs were aware of 11 (41%). 
Of 21 registries identified by the RC, RD-Connect and Orphanet did not have a record of 10 (48%). Of the 29 glucose 
RCs, the awareness and participation rate in an international registry was highest for rare diabetes at 75 and 56% 
respectively. Of the 37 sex development RCs, the corresponding rates were highest for disorders of sex development 
at 70 and 52%. Of the 33 adrenal RCs, the rates were highest for adrenocortical tumours at 68 and 43%. Of the  
43 pituitary RCs, the rates were highest for pituitary adenomas at 43 and 29%. Of the 31 genetic tumour RCs, the rates 
were highest for MEN1 at 26 and 9%. For the remaining conditions, awareness and participation in registries was less 
than 25%.
Conclusion: Although there is a need to develop new registries for rare endocrine conditions, there is a more 
immediate need to improve the awareness and participation in existing registries.
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Introduction
Rare diseases or rare conditions are defined by the 
European Union (EU) as life-threatening or chronic 
debilitating conditions with a prevalence rate of less than 
5 per 10 000 (European Commission (EC) Regulation # 
141/2000). The management of these conditions requires 
coalesced efforts over the life time of the patient to reduce 
morbidity and mortality in affected individuals. Rare 
endocrine conditions pose a particular challenge due to 
current knowledge gaps regarding long-term outcome, 
lack of expert and evidence-based multidisciplinary care 
resulting in substantial variation in care. Registries have 
the potential to improve patient care and healthcare 
planning in those with rare conditions; they enable 
pooling of data for research activities and surveillance; 
by creating a virtual environment of collaboration, 
they can also facilitate communication between 
professionals and affected individuals (EURCERD core 
recommendations on rare disease patient registration 
and data collection. http://www.eucerd.eu/wpcontent/
uploads/2013/06/EUCERD_Recommendat ions_
RDRegistryDataCollectionadopted.pdf; last accessed May 
25, 2018). Multicentre collaboration between centres of 
expertise within registries also plays a vital role in the 
development of clinical benchmarks, thereby acting as a 
platform for quality improvement.
Over 800 rare disease registries are reported to exist in 
Europe with some operating on an international, national 
or regional scale (1, 2). A requirement for international 
registration of patients with rare conditions is widely 
recognized and supported by the EU (International Rare 
Disease Research Consortium. http://wwwirdirc.org; last 
accessed May 11 2018) (3); European initiatives including 
Orphanet (https://www.orpha.net/consor/cgi-bin/index.
php; last accessed August 1 2018) and RD-Connect (http://
catalogue.rd-connect.eu/; last accessed August 1 2018) (4) 
have attempted to identify existing registries. The use of 
cross-border international registries offers clear benefits 
for collaboration and standardized data collection for rare 
conditions.
European Reference Networks (ERNs) are networks of 
reference centres (RCs) across Europe that aim to manage 
rare medical conditions that require specialist attention 
and a concentration of knowledge and resources (5, 6). 
The ERN for rare endocrine conditions (Endo-ERN) is 
the largest ERN with 71 RCs from 19 member states 
(endo-ern.eu). It currently includes 42 conditions with 
orphacodes that are organised into eight broad categories 
termed ‘Main Thematic Groups (MTGs)’ which include 
Adrenal Disorders, Disorders of Calcium and Phosphate 
Homeostasis, Genetic Disorders of Glucose and Insulin 
Homeostasis, Genetic Endocrine Tumour Syndromes, 
Growth and Genetic Obesity Syndromes, Pituitary 
Disorders, Sex Development and Maturation Disorders 
and Thyroid Disorders. It is estimated that these 71 RCs 
may care for over 60 000 patients with the above groups 
of conditions.
Although registries are regarded as essential for Endo-
ERN, knowledge on the range of registries that exist for 
cross-border sharing of information on rare endocrine 
conditions in Europe is scarce. Furthermore, the extent 
of awareness, participation and availability of registries 
for the wide range of conditions within Endo-ERN is 
unclear. The development of Endo-ERN provided a perfect 
opportunity to identify registries that already exist in 
Europe for the rare endocrine conditions that have been 
included in the network and to also determine the extent 
of engagement in registries of health professionals within 
an expert network such as Endo-ERN.
Methods
To identify the registries that currently exist for rare 
endocrine conditions, the investigators examined 
the outputs from Orphanet (https://www.orpha.net/
consor/cgi-bin/index.php; last accessed August 1 2018) 
and RD-Connect (http://catalogue.rd-connect.eu/; last 
accessed August 1 2018) projects using Orphacodes 
for all conditions and, in addition, surveyed Endo-ERN 
members between October and November 2016. For 
the purpose of this mapping exercise, an international 
registry was defined as a patient registry that collected 
uniform information on individual patients (7) and 
was used by more than one country within Europe and 
where the coordinating centre was based in Europe. 
Within Endo-ERN, all 71 RC leads from 19 countries 
were invited to complete a survey documenting their 
awareness of international, national and local registries 
and active participation in registries at an international, 
national and local level. RC leads were asked to complete 
their responses, for each condition that they had been 
approved for, using preset answer categories (Yes/No). To 
understand future priorities, respondents were asked to 
denote 1–5 on a Likert scale to assess the level of priority 
for need of a registry for a given condition, where 5 was 
the greatest priority.
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Statistical analysis
Categorical data were analysed using descriptive statistics. 
Microsoft Excel 2016 (Microsoft Corp, Redmond, WA, 
USA) was used to collate and analyse numerical data. 
Median and range values were obtained for the dataset.
Results
Response rate
A response rate of 82% (58/71 RC) was obtained. Twenty-
five (35%) RCs were involved in six or more themes and 26 
(37%) RCs were involved in one theme only. The average 
response rate across all eight themes was 80% (Fig. 1).
Adrenal registries
Of the 33 centres surveyed within the adrenal theme, 
awareness of an international registry was 68% for 
adrenocortical tumours, 57% for phaeochromocytoma, 
54% for congenital adrenal hyperplasia (CAH), 46% for 
bilateral macro- and micro-nodular adrenal hyperplasia 
and 29% for adrenal insufficiency (Table 1). International 
registry participation rates were 39, 30, 18, 21 and 6% 
respectively. A median priority score for future registry 
development of 5 was attributed to adrenocortical 
tumours, phaeochromocytoma and CAH (Fig. 2).
Registries for disorders of calcium and 
phosphate homeostasis
Of the 29 centres within the calcium/phosphate theme, 
international registry awareness was 17% for disorders 
of phosphate disturbances, 13% for hypercalcaemia and 
4% for hypocalcaemia; participation was 8, 8 and 0%, 
respectively. Awareness and participation in local registries 
was higher for all conditions (Table  1). Hypocalcaemia 
and hypophosphataemia were given a median priority 
score of 5 (Fig. 2).
Registries for genetic disorders of glucose and 
insulin homeostasis
Of the 29 centres within the glucose theme, participants 
reported the highest rates of awareness and participation 
in an international registry for rare diabetes (75 and 
56%, respectively) (Table  1). Median priority scores 
of 5 were attributed to rare diabetes and congenital 
hyperinsulinism (Fig. 2).
Registries for genetic endocrine 
tumour syndromes
Of the 31 centres reporting on the rare genetic tumour 
theme, 26% reported an international registry awareness 
for MEN1 and 9% reported participation (Table  1). 
Seventy percent reported awareness and participation in 
local registries for MEN1. All conditions were rated as 5 on 
priority scoring (Fig. 2).
Registries for growth and genetic 
obesity syndromes
Of the 30 centres within the growth theme, local and 
national registry awareness and participation for all 
conditions was greater than that for international 
registries. International registry awareness was highest for 
Prader–Willi syndrome at 17% with a participation level 
of 10% (Table 1). Participation in international registries 
for Silver–Russell syndrome, Beckwith–Wiedemann 
syndrome and Noonan syndrome was 3%. All conditions 
within the growth theme were given a median priority 
score of 5 (Fig. 2).
Pituitary registries
Of the 43 centres within the pituitary theme, awareness 
and participation in an international registry was greatest 
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Figure 1
Response rates for reference centres (RC) categorised 
according to the Main Thematic Groups (MTG). Of the 71 RC, 
58 (82%) responded to the survey. The mean response rate 
across 8 themes was 80%. MTG1, adrenal; MTG2, calcium and 
phosphate; MTG3, glucose and insulin; MTG4, endocrine 
tumours; MTG5, growth and obesity; MTG6, pituitary; MTG7, 
sex development; MTG8, thyroid.
Downloaded from Bioscientifica.com at 01/22/2020 09:06:10AM
via University of Glasgow
Eu
ro
pe
an
 Jo
ur
na
l o
f E
nd
oc
ri
no
lo
gy
180:1 92Clinical Study S R Ali and others Registries for rare endocrine 
conditions
https://eje.bioscientifica.com
Ta
b
le
 1
 
Su
rv
ey
 o
f E
nd
o-
ER
N
 r
ef
er
en
ce
 c
en
tr
es
 (R
C)
 s
ho
w
in
g 
ex
te
nt
 o
f a
w
ar
en
es
s 
an
d 
pa
rt
ic
ip
at
io
n 
in
 r
ar
e 
di
se
as
e 
re
gi
st
ri
es
 fo
r 
co
nd
iti
on
s 
in
cl
ud
ed
 in
 E
nd
o-
ER
N
 w
ith
in
 
th
e 
8 
br
oa
d 
m
ai
n 
th
em
at
ic
 g
ro
up
s 
(M
TG
). 
D
at
a 
is
 p
re
se
nt
ed
 a
s 
n 
or
 n
 (%
)
En
d
o
-E
R
N
 M
TG
s 
an
d
 c
o
n
d
it
io
n
s 
su
rv
ey
ed
R
C
 s
u
rv
ey
ed
 
R
C
 r
es
p
o
n
d
ed
 
A
w
ar
en
es
s 
o
f 
re
gi
st
ri
es
 
Pa
rt
ic
ip
at
io
n
 in
 r
eg
is
tr
ie
s 
In
te
rn
at
io
na
l
N
at
io
na
l
Lo
ca
l
In
te
rn
at
io
na
l
N
at
io
na
l
Lo
ca
l
M
TG
1.
 A
dr
en
al
33
28
 (8
5)
 
Ph
ae
oc
hr
om
oc
yt
om
a
16
 (5
7)
7 
(2
5)
16
 (5
7)
10
 (3
6)
6 
(2
1)
14
 (5
0)
 
A
dr
en
oc
or
tic
al
 c
ar
ci
no
m
a
20
 (7
1)
15
 (5
4)
15
 (5
4)
13
 (4
6)
6 
(2
1)
15
 (5
4)
 
C
or
tis
ol
 p
ro
du
ci
ng
 a
de
no
m
as
19
 (6
8)
8 
(2
9)
12
 (4
3)
12
 (4
3)
8 
(2
9)
12
 (4
3)
 
B
ila
te
ra
l m
ac
ro
no
du
la
r 
hy
pe
rp
la
si
a
13
 (4
6)
4 
(1
4)
11
 (3
9)
8 
(2
9)
4 
(1
4)
11
 (3
9)
 
B
ila
te
ra
l m
ic
ro
no
du
la
r 
hy
pe
rp
la
si
a
13
 (4
6)
3 
(1
0)
10
 (3
6)
7 
(2
5)
3 
(1
1)
10
 (3
6)
 
(P
ri
m
ar
y)
 a
dr
en
al
 in
su
ffi
ci
en
cy
8 
(2
9)
5 
(1
8)
13
 (4
6)
2 
(7
)
5 
(1
8)
13
 (4
6)
 
C
on
ge
ni
ta
l a
dr
en
al
 h
yp
er
pl
as
ia
15
 (5
4)
15
 (5
4)
17
 (6
1)
6 
(2
1)
15
 (5
4)
17
 (6
1)
 
Fa
m
ili
al
 h
yp
er
al
do
st
er
on
is
m
6 
(2
1)
4 
(1
4)
8 
(2
9)
3 
(1
1)
4 
(1
4)
6 
(2
1)
M
TG
2.
 C
al
ci
um
 a
nd
 p
ho
sp
ha
te
29
24
 (8
3)
 
H
yp
er
ca
lc
ae
m
ia
3 
(1
3)
4 
(1
7)
11
 (4
6)
2 
(8
)
4 
(1
7)
11
 (4
6)
 
H
yp
oc
al
ca
em
ia
1 
(4
)
2 
(8
)
13
 (5
4)
0 
(0
)
2 
(8
)
13
 (5
4)
 
Ph
os
ph
at
e 
di
st
ur
ba
nc
es
4 
(1
7)
4 
(1
7)
15
 (6
3)
2 
(8
)
2 
(8
)
15
 (6
3)
M
TG
3.
 G
lu
co
se
 a
m
d 
in
su
lin
29
24
 (8
3)
 
H
yp
er
in
su
lin
is
m
5 
(2
1)
9 
(3
8)
10
 (4
2)
3 
(1
2)
6 
(2
4)
9 
(3
8)
 
In
su
lin
-r
es
is
ta
nc
e 
sy
nd
ro
m
e
12
 (5
0)
8 
(3
3)
6 
(2
4)
9 
(3
8)
8 
(3
3)
6 
(2
4)
 
Ra
re
 d
ia
be
te
s 
m
el
lit
us
18
 (7
5)
16
 (6
7)
12
 (5
0)
14
 (5
6)
16
 (6
7)
12
 (5
0)
M
TG
4.
 E
nd
oc
ri
ne
 tu
m
ou
rs
31
23
 (7
4)
 
M
EN
 ty
pe
 1
6 
(2
6)
8 
(3
5)
16
 (7
0)
2 
(9
)
8 
(3
5)
16
 (7
0)
 
M
EN
 ty
pe
 2
5 
(2
2)
4 
(1
7)
15
 (6
5)
1 
(4
)
4 
(1
7)
15
 (6
5)
 
C
ar
ne
y 
co
m
pl
ex
1 
(4
)
1 
(4
)
8 
(3
5)
0 
(0
)
1 
(4
)
7 
(3
0)
 
H
er
ed
ita
ry
 p
ha
eo
ch
ro
m
oc
yt
om
a–
pa
ra
ga
ng
lio
m
a
8 
(3
5)
7 
(3
0)
14
 (6
1)
4 
(1
7)
7 
(3
0)
14
 (6
1)
 
Vo
n 
H
ip
pe
l L
in
da
u 
sy
nd
ro
m
e
6 
(2
6)
4 
(1
7)
15
 (6
5)
3 
(1
3)
4 
(1
7)
15
 6
5)
M
TG
5.
 G
ro
w
th
 a
nd
 o
be
si
ty
30
24
 (8
0)
 
Pr
ad
er
–W
ill
i a
nd
 P
ra
de
r–
W
ill
i-l
ik
e 
sy
nd
ro
m
e
5 
(2
1)
16
 (6
7)
19
 (7
9)
3 
(1
3)
14
 (5
8)
18
 (7
5)
 
Si
lv
er
 R
us
se
ll 
sy
nd
ro
m
e
3 
(1
3)
9 
(3
8)
10
 (4
2)
1 
(4
)
7 
(2
9)
9 
(3
8)
 
B
ec
kw
ith
 W
ie
de
m
an
n 
sy
nd
ro
m
e
1 
(4
)
3 
(1
3)
6 
(2
4)
1 
(4
)
3 
(1
2)
5 
(2
1)
 
N
oo
na
n 
sy
nd
ro
m
e
2 
8)
9 
(3
8)
10
 (4
2)
1 
(4
)
9 
(3
8)
9 
(3
8)
 
G
H
 r
es
is
ta
nc
e 
sy
nd
ro
m
es
3 
(1
3)
5 
(2
1)
9 
(3
8)
1 
(4
)
5 
(2
1)
9 
(3
8)
M
TG
6.
 P
itu
ita
ry
43
35
 (8
1)
 
Pi
tu
ita
ry
 a
de
no
m
a
14
 (4
3)
17
 (4
9)
24
 (6
9)
10
 (2
9)
17
 (4
9)
24
 (6
9)
 
C
on
ge
ni
ta
l h
yp
op
itu
ita
ri
sm
7 
(2
0)
12
 (3
4)
19
 (5
4)
5 
(1
4)
11
 (3
1)
19
 (5
4)
 
A
cq
ui
re
d 
hy
po
pi
tu
ita
ri
sm
9 
(2
5)
13
 (3
7)
20
 (5
7)
6 
(1
7)
13
 (3
7)
20
 (5
7)
M
TG
7.
 S
ex
 d
ev
el
op
m
en
t
37
27
 (7
3)
 
Se
x 
ch
ro
m
os
om
e 
D
SD
18
 (6
7)
12
 (4
4)
18
 (6
7)
13
 (4
8)
10
 (3
7)
18
 (6
7)
 
46
, X
X 
D
SD
19
 (7
0)
12
 (4
4)
17
 (6
3)
14
 (5
2)
10
 (3
7)
17
 (6
3)
 
46
, X
Y 
D
SD
19
 (7
0)
13
 (4
8)
18
 (6
7)
14
 (5
2)
11
 (4
1)
18
 (6
7)
 
C
on
ge
ni
ta
l h
yp
og
on
ad
ot
ro
ph
ic
 h
yp
og
on
ad
is
m
15
 (5
6)
10
 (3
7)
16
 (5
9)
9 
(3
3)
10
 (3
7)
16
 (5
9)
M
TG
8.
 T
hy
ro
id
35
28
 (8
0)
 
Th
yr
oi
d 
si
gn
al
lin
g 
di
so
rd
er
s
6 
(2
1)
4 
(1
4)
8 
(2
9)
2 
(7
)
4 
(1
4)
7 
(2
5)
 
C
on
ge
ni
ta
l h
yp
ot
hy
ro
id
is
m
2 
(7
)
18
 (6
4)
12
 (4
3)
0 
(0
)
15
 (5
4)
11
 (3
9)
 
C
on
ge
ni
ta
l h
yp
er
th
yr
oi
di
sm
1 
(4
)
1 
(4
)
4 
(1
4)
0 
(0
)
1 
(4
)
3 
(1
1)
 
N
on
-m
et
as
ta
tic
 th
yr
oi
d 
m
ac
ro
-c
ar
ci
no
m
a
5 
(1
8)
15
 (5
4)
16
 (5
7)
0 
(0
)
15
 (5
4)
16
 (5
7)
 
Ra
di
oi
od
in
e 
se
ns
iti
ve
 d
iff
er
en
tia
te
d 
th
yr
oi
d 
ca
nc
er
3 
(1
1)
8 
(2
9)
12
 (4
3)
0 
(0
)
8 
29
)
12
 (4
3)
 
N
on
-m
et
as
ta
tic
 m
ed
ul
la
ry
 th
yr
oi
d 
ca
rc
in
om
a
4 
(1
4)
11
 (3
9)
14
 (5
0)
0 
(0
)
11
 (3
9)
14
 (5
0)
Downloaded from Bioscientifica.com at 01/22/2020 09:06:10AM
via University of Glasgow
Eu
ro
pe
an
 Jo
ur
na
l o
f E
nd
oc
ri
no
lo
gy
180:1 93Clinical Study S R Ali and others Registries for rare endocrine 
conditions
https://eje.bioscientifica.com
for pituitary adenomas, with 43% awareness and 29% 
participation (Table  1). Pituitary adenoma was the only 
condition given a median priority score of 5 (Fig. 2).
Registries for sex development and maturation
Of the 37 centres within the sex development theme, 70% 
reported an awareness and 52% reported participation in 
international registries for 46, XX and 46, XY disorders or 
differences of sex development (DSD) (Table 1). Despite 
greater awareness of international registries, rates of 
participation in local registries were higher than those 
for international registries for all DSD (49% vs 39%). 
All conditions within the sex development group were 
given a median priority score of 5 (Fig. 2).
Thyroid registries
Of the 35 centres within the thyroid theme, international 
registry awareness was greatest for thyroid signalling 
disorders (21%), however, participation was only 7% 
(Table  1). Out of the six conditions, four (thyroid 
signalling disorders, thyroid carcinoma, radioiodine 
sensitive differentiated thyroid carcinoma (RI sensitive 
DTC), non-metastatic medullary thyroid disease) were 
rated as 5 (Fig. 2).
Comparison of Endo-ERN, Orphanet 
and RD-Connect
For endocrine conditions within the main thematic groups 
of Endo-ERN, 33 registries were identified through the 
above survey of Endo-ERN and the search of the Orphanet 
and RD-Connect databases (Table 2). Endo-ERN members 
identified 21 registries, Orphanet identified 20 and 
RD-Connect identified 7. Of the 27 registries identified via 
Orphanet or RD-Connect, Endo-ERN members reported 
11 (41%) (Fig.  3). Amongst the international registries 
identified, several existed for discrete groups of conditions 
including Adrenal, Genetic Disorders of Glucose and 
Insulin Homeostasis and Growth and Obesity Syndromes. 
Three international registries were identified by Endo-ERN, 
Orphanet and RD-Connect, and these included ERCUSYN 
(European Registry on Cushing’s Syndrome, www.lb.de/
ercusyn), EUROWABB (EU Rare Diseases Registry for 
Wolfram Syndrome, Alstrom Syndrome, Bardet–Biedl 
Syndrome and Other Rare Diabetes Syndromes, www.
euro-wabb.org) and I-DSD (International Registry for 
Disorders of Sex Development, www.i-dsd.org) which 
also includes CAH. Of the six industry-led registries that 
were identified by Endo-ERN RC, none were identified 
in Orphanet and RD-Connect (Table 2), whereas, of the 
27 non-commercial registries, all were identified through 
Orphanet, RD-Connect or both.
Discussion
This contemporary survey of registries has clearly revealed 
that whilst there are several registries for a range of rare 
endocrine conditions, there are also several gaps in 
coverage of conditions. In addition, there are gaps in the 
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Figure 2
Views on future priorities categorised according to the Main 
Thematic Groups (MTG). A score of 5 (highest priority for need 
of a registry) was attributed to all conditions within MTG4, 
MTG5 and MTG7. MTG1, adrenal; MTG2, calcium and 
phosphate; MTG3, glucose and insulin; MTG4, endocrine 
tumours; MTG5, growth and obesity; MTG6, pituitary; MTG7, 
sex development; MTG8, thyroid.
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level of awareness and use as well as the international 
profile of existing international registries.
Clear patterns were observed for awareness and 
participation of international registries. For conditions 
including disorders of calcium and phosphate, endocrine 
tumour syndromes, growth syndromes and pituitary and 
thyroid disease, there was greater awareness of local or 
national registries rather than international registries. 
On the other hand, for other groups of conditions such 
as adrenal disorders, insulin resistance syndrome, rare 
diabetes mellitus and DSD, there was a high level of 
awareness and participation in international registries.
The increased awareness of international registries 
amongst the Endo-ERN participants for particular 
subgroups of conditions may be attributed to the presence 
of already established secure Web-based registries such 
as those listed within Orphanet and RD-Connect and/
or to large international collaboration of RC within a 
given theme prior to the establishment of Endo-ERN, 
for example, the glucose, adrenal and DSD themes. 
The SWEET registry is an example of a registry that was 
initially developed to cover type 1 diabetes mellitus; 
however, in doing so, it has also become a powerful 
resource for rare forms of diabetes (8). Although the use 
of international, cross-border registries may be primarily 
linked to the availability and awareness of registries, 
many RC leads were not aware of international registries 
or did not use these registries despite being aware of them. 
Reasons for not participating in registries require further 
exploration, however, previous studies have reported that 
these may include failure to obtain consent and lack of 
time or personnel (9). It is also possible that an absence of 
transparent quality indicators that can be used to assess 
registries (10) may also play a role. However, the current 
study suggests that lack of awareness of a registry may be 
a very important factor. Conditions for which a registry 
was considered a high priority were often those for which 
international registries already existed. There may be 
several explanations for this finding. Firstly, it may simply 
reflect the respondent’s lack of awareness of the existing 
registries. Alternatively, it may reflect the respondent’s 
belief that the existing registry needs to remain high 
priority or the respondent’s view that another new registry 
needs to be developed.
Databases such as Orphanet and RD-Connect have 
been developed to facilitate greater awareness of registries 
for rare conditions and may also pave the way towards 
improving the quality of registries. However, it is important 
to note that current databases of rare disease registries such as 
Orphanet and RD-Connect did not have a record of several 
international registries that are currently led from Europe. 
This was noted particularly for rare disease registries led 
by industry. Given that rare disease registries have to enter 
their details on these databases, the discordance suggests a 
mutual lack of awareness between these databases and the 
rare disease registries of the respective platforms. It is possible 
that registries led by industry have been designed specifically 
for post-marketing surveillance of specific drugs for a fixed 
period with limited applicability to the wider community 
and long-term sustainability may not be a priority, and 
this may explain their lack of visibility on Orphanet and 
RD-Connect. On the other hand, these registries are generally 
well resourced with a clear objective, and it is possible that 
the data within them are of high quality. In the field of rare 
conditions, greater partnership with industry is generally 
supported by all stakeholders (European Medicines Agency 
Report on the Patient Registries Workshop (28 October 2016) 
http://www.ema.europa.eu/docs/en_GB/document_library/
Report/2017/02/WC500221618.pdf; last accessed September 
13 2018) and is necessary for effective use of limited resources.
Figure 3
International registries for rare endocrine 
conditions. 33 registries were identified 
via Endo-ERN members, Orphanet and 
RD-Connect.
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Whilst the current survey shows that many centres 
are collecting data in local registries, participation in 
international registries is often considered to be the 
gold standard for improving the quality of research, 
improving patient care and the external validity of 
registries for rare conditions (11, 12, 13). However, 
one of the most challenging aspects of developing an 
international detailed disease registry is the requirement 
of a common dataset based on a standardised data entry 
(10). It is highly likely that these separate registries will 
have several fields that will be common to all. Thus, the 
existence of a group of local and national registries should 
be viewed positively as these registries can pave the way 
towards the development of a common dataset for an 
international registry. Another hurdle in the development 
of multinational registries has long been the existence of 
country-specific ethical regulations for the development 
and use of such registries. The recently issued General 
Data Protection Regulation (GDPR) by the EU provides a 
welcome opportunity to overcome these problems (14).
With the recent development of Endo-ERN, 
consideration should also be given to effective collation 
of available resources and development of a virtual 
environment that serves the objectives of this ERN and one 
that acts as a model for the wider endocrine community 
as well as other rare disease networks (15). The European 
Registries for Rare Endocrine Conditions (EuRRECa) 
[eurreca.net] is a new project that aims to address gaps 
raised in the above survey by developing a core registry 
and an e-reporting programme for all rare endocrine 
conditions that are covered within Endo-ERN. EuRRECa 
will not only increase the awareness of registries amongst 
patients and professionals by facilitating interaction 
between existing and new disease registries within Endo-
ERN, it will also assess the quality of existing registries 
using agreed guidance (11, 12) and signpost the endocrine 
community to these registries. By partnering with the 
European Society for Endocrinology and the European 
Society for Paediatric Endocrinology, the project will offer 
its resources to a wider group of health care professionals 
beyond Endo-ERN. It is also anticipated that the project 
will act as a bridge between the endocrine community 
and global initiatives that seek to create an inventory of 
existing registries.
In summary, whilst there is a clear need to develop 
new detailed disease registries, there is also a need to 
improve the awareness and signposting of existing 
registries. A common platform that can be used by the 
whole endocrine community and which directs the user 
to high-quality detailed disease registries has the potential 
to achieve this objective.
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